Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Incyte has earned a $50 million milestone payment from Eli Lilly & Co. for the initiation of Phase III trials on baricitinib, Incyte’s oral treatment for rheumatoid arthritis. Incyte disclosed the payment a week after FDA approved Pfizer’s oral rheumatoid arthritis drug Xeljanz. Both drugs are JAK inhibitors, which target signaling pathways inside cells that play a role in the inflammation involved in arthritis. Pfizer says Xeljanz is the first JAK inhibitor for rheumatoid arthritis and the first new oral rheumatoid drug in more than 10 years.
This article has been sent to the following recipient: